Nanoxel Dosage & Drug Information

Concise Prescribing Info

Contents

Paclitaxel (nanoparticle inj)

Indications/Uses

Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse w/in 6 mth of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Dosage/Direction for Use

220 mg/m² IV over 1 hr 3 wkly.

Contraindications

Should not be used in solid tumor ovary, breast & NSCLC patients w/ baseline neutrophil count of <1500 cells/mm³ or in patients w/ AIDS-related Kaposi's sarcoma w/ baseline neutrophil count of <1000 cells/mm³. Pregnancy & lactation.

Special Precautions

Perform blood counts frequently in order to monitor the occurrence of bone marrow suppression, primarily neutropenia. Monitor infusion site for possible infiltration during therapy. Hepatic & renal impairment. Childn.

Adverse Reactions

Neutropenia, febrile neutropenia, leukopenia, thrombocytopenia, anemia, palpitation, tachycardia, hypotension, HTN, cough, dyspnea, neuropathy, body pain, myalgia, nausea, vomiting, diarrhea, oral mucositis, rash, pruritus; bilirubin, SGOT/SGPT & alkaline phosphatase elevation; inj site reaction.

View ADR Monitoring Form

Drug Interactions

Cytochrome P450 isoenzymes CYP2C8 & CYP3A4 substrates or inhibitors.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CD01 - paclitaxel ; Belongs to the class of taxanes from plant alkaloids and other natural products. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

Nanoxel inj 20 mg/mL

Packing/Price

(vial) 1.5 mL x 1's;15 mL x 1's;5 mL x 1's

Nanoxel

paclitaxel

Manufacturer:

Fresenius Kabi

Distributor:

Zuellig